Drugs / MK-1045
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07363590 | Feb 2026 → Jul 2029 expected | rheumatoid arthritis, systemic lupus erythematosus | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT06189391 | Mar 2021 → Sep 2028 expected | B-cell non-Hodgkin lymphoma | MSD R&D (China) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07519772 | May 2026 → Jul 2030 expected | diffuse large B-cell lymphoma, follicular lymphoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05579132 | Nov 2022 → Jun 2028 expected | acute lymphoblastic leukemia | MSD R&D (China) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07709000 | Aug 2026 → Nov 2033 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07634471 | Jun 2026 → Jul 2032 expected | follicular lymphoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07570173 | May 2026 → Oct 2033 expected | B-cell acute lymphoblastic leukemia | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-1045 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07634471 ↗ |
| Modality | Other / unclassified | “MK-1045 is a type of treatment called immunotherapy.” NCT07634471 ↗ |
| Route | Intravenous | “MK-1045 is administered by IV infusion once a week (QW), 4 weeks per treatment cycle, starting with 2 cycles of induction treatment.” NCT05579132 ↗ |